Xeris Biopharma Holdings Inc stock is traded at $13.08, with a volume of 12,342,163. It is up +25.05% in the last 24 hours and up +29.12% over the past month. Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Previous Close:
$10.46
Open:
$12.51
24h Volume:
12,342,163
Relative Volume:
3.90
Market Cap:
$2.38B
Revenue:
$314.85M
Net Income/Loss:
$12.01M
P/E Ratio:
199.69
EPS:
$0.0655
Net Cash Flow:
$47.52M
1W Performance:
+21.67%
1M Performance:
+29.12%
6M Performance:
+109.95%
1Y Performance:
+32.52%
1-Day Range:
$12.32$13.74
1-Week Range:
$10.08$13.74
52-Week Range:
$5.25$13.74
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings IncSector
HealthcarePhone
844-445-5704Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS